Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598630 | 0.82 | CA1 (0.46) | CA1CA2CA4EPHX1TRPA1 | |
| SCHEMBL16191287 | 0.82 | CA1 (0.46) | CA1CA2CA4EPHX1TRPA1 | |
| SCHEMBL24031427 | 0.80 | CA1 (0.43) | CA1CA2CA4EPHX1TRPA1 | |
| SCHEMBL24142309 | 0.79 | CA1 (0.33) | CA1CA2CA4 | |
| SCHEMBL11361007 | 0.79 | CA1 (0.48) | CA1CA2CA4EPHX1 | |
| SCHEMBL23797524 | 0.78 | CA1 (0.42) | CA1CA2CA4EPHX1 | |
| SCHEMBL24571704 | 0.78 | CA1 (0.42) | CA1CA2CA4EPHX1 | |
| SCHEMBL6236455 | 0.78 | CA1 (0.48) | CA1CA2CA4EPHX1TRPA1 | |
| SCHEMBL678469 | 0.78 | CA1 (0.42) | CA1CA2CA4EPHX1 | |
| SCHEMBL14639771 | 0.78 | CA1 (0.48) | CA1CA2CA4EPHX1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019023316-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | SUTRO BIOPHARMA, INC. (US) | 2019-01-31 | — | — | WO | disclosed |